{"denoms":[{"counts":[{"groupId":"BG000","value":"31"}],"units":"Participants"}],"groups":[{"description":"All patients receive same therapy\n\nFludarabine: 30 mg/m2/day IV x 6 days\n\nMelphalan: 100 mg/m2/day IV x 1 day\n\nTotal Body Radiation: 200 cGy on Day 0\n\nCord Blood: 2 cord blood units IV","id":"BG000","title":"Fludarabine/Melphalan/TBI"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"21","upperLimit":"68","value":"57"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"31"}],"units":"Participants"}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"22"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"31"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"denoms":[{"counts":[{"groupId":"BG000","value":"0"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Race and Ethnicity were not collected from any participant.","title":"Race and Ethnicity Not Collected","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"31"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"31"}],"units":"Participants"}],"title":"United States"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"10"}],"title":"0"},{"measurements":[{"groupId":"BG000","value":"19"}],"title":"1"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"2"}],"denoms":[{"counts":[{"groupId":"BG000","value":"31"}],"units":"Participants"}]}],"description":"Eastern Cooperative Oncology Group (ECOG) Performance Status:\n\n* 0 - Asymptomatic (Fully active, able to carry on all predisease activities without restriction)\n* 1 - Symptomatic but completely ambulatory (Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature. For example, light housework, office work)\n* 2 - Symptomatic, \\<50% in bed during the day (Ambulatory and capable of all self care but unable to carry out any work activities. Up and about more than 50% of waking hours)","paramType":"COUNT_OF_PARTICIPANTS","title":"Performance Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Acute Lymphoblastic Leukemia (ALL)"},{"measurements":[{"groupId":"BG000","value":"11"}],"title":"Acute Myeloid Leukemia (AML)"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Hodgkin's Disease (HD)"},{"measurements":[{"groupId":"BG000","value":"8"}],"title":"Myelodysplastic Syndromes (MDS)"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Myeloproliferative Disorder (MPD)"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":"Non-Hodgkin Lymphoma (NHL)"}],"denoms":[{"counts":[{"groupId":"BG000","value":"31"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Disease","unitOfMeasure":"Participants"}],"populationDescription":"The two participants found to be ineligible after being consented and registered were excluded from the analysis."}